![]() ![]() These data (Presentation #D3T01.1F) and 25 additional abstracts demonstrating Bristol Myers Squibb’s robust body of research in dermatology are being presented at the European Academy of Dermatology and Venereology (EADV) Congress, taking place September 7-10, 2022. ![]() At 112 weeks of Sotyktu treatment, modified non-responder imputation (mNRI) response rates were 82.4% for Psoriasis Area and Severity Index (PASI) 75, 55.2% for PASI 90 and 66.5% for static Physician's Global Assessment (sPGA) 0/1. This analysis assessed patients from the pivotal POETYK PSO-1 trial who transitioned into the LTE trial. PRINCETON, N.J.-(BUSINESS WIRE)- Bristol Myers Squibb (NYSE:BMY) today announced new two-year results from the POETYK PSO long-term extension (LTE) trial demonstrating clinical efficacy was maintained with continuous Sotyktu™ (deucravacitinib) treatment in adult patients with moderate-to-severe plaque psoriasis. New analysis to be presented at the 2022 European Academy of Dermatology and Venereology Congress as part of 26 company-sponsored scientific presentations, demonstrating ongoing commitment to dermatology research ![]() Results add to the growing body of evidence and reinforce the efficacy profile of Sotyktu, a once-daily, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of moderate-to-severe plaque psoriasis ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |